News

RSS

No Evidence to Support Routine Use of Aspirin in Women for Primary Prevention (4 Dec 2014)

Although once widely recommended, aspirin for primary prevention has lost favor in recent years, as the large number of bleeding complications appeared to offset the reduction in cardiovascular events. But at the same time evidence has emerged demonstrating the long-term effect of aspirin in preventing colorectal cancer, leading some to think that the risk-to-benefit equation…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Adherence to Mediterranean Diet Linked to Marker of Healthy Aging (2 Dec 2014)

Following a string of recent successes and favorable publicity for the Mediterranean Diet, a a new study published in The BMJ finds that women who more closely followed a Mediterranean diet had longer telomeres, a key measure of healthy aging. The new report is based on data from 4676 women in the Nurses’ Health Study who completed…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Study Suggests Epinephrine for Cardiac Arrest May Be Harmful (1 Dec 2014)

Epinephrine has been a cornerstone of therapy during cardiac resuscitation after cardiac arrest because of its well-established ability to stimulate the heart and increase the probability of a return of spontaneous circulation (ROSC). In recent years, however, concerns have been raised that people treated with epinephrine may have worse neurological outcomes following their resuscitation. In…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

FDA Approves New Noninvasive FFR Technology (28 Nov 2014)

The FDA said Wednesday that it had granted approval to a novel technology that noninvasively measures fractional flow reserve (FFR) using data obtained from a CT scan of the heart. In recent years a catheter-based form of FFR has been used by interventional cardiologists during catheterization procedures to measure the pressure gradient in partially blocked…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)

Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Encouraging Results for Two New Drugs for Hyperkalemia (21 Nov 2014)

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. In a phase 3 study, published online in the New England Journal of Medicine, researchers first randomized…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Encouraging Results For Two New Drugs For Hyperkalemia (21 Nov 2014)

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.  

U.S. Proposal Would Greatly Expand Transparency of Clinical Trials (19 Nov 2014)

The U.S. Department of Health and Human Services today proposed new rules that would greatly expand the number of clinical trials that companies and researchers are required to report. “Medical advances would not be possible without participants in clinical trials,” said NIH Director Francis Collins. “We owe it to every participant and the public at large…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Losartan No Better Than Atenolol in Marfan’s Syndrome (18 Nov 2014)

Beta-blockers have been the standard treatment for people with Marfan’s syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people. The goal of treatment is to prevent or slow down the dilation of the aorta and avoid aortic dissection, the main cause of death. In recent years, studies have raised the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Don’t Count the Numbers. HDL Function Looks Like the Key (18 Nov 2014)

A new study offers important evidence explaining the protective role of HDL cholesterol against cardiovascular disease. Previous studies with drugs that increase HDL levels, including niacin and CETP inhibitors, have not been found beneficial. The new study suggests that simply increasing HDL levels isn’t useful. Instead, cholesterol efflux, the ability of HDL to remove cholesterol from…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.